[ORPN] Bioblast Pharma Ltd.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.12 Change: -0.04 (-3.45%)
Ext. hours: Change: 0 (0%)

chart ORPN

Refresh chart

Strongest Trends Summary For ORPN

ORPN is in the medium-term up 51% in 3 months. In the long-term down -47% in 1 year and down -97% below S&P in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-20 K Cash From Operating Activities-3.56 M Gross Profit
Net Profit-3.3 M Operating Profit-3.32 M Total Assets29.85 M Total Current Assets29.76 M
Total Current Liabilities1.74 M Total Debt Total Liabilities1.75 M Total Revenue
Technical Data
High 52 week3.07 Low 52 week0.77 Last close1.36 Last change-3.55%
RSI61.31 Average true range0.2 Beta0.66 Volume16.59 K
Simple moving average 20 days13.19% Simple moving average 50 days26.49% Simple moving average 200 days-4.35%
Performance Data
Performance Week16.16% Performance Month30.77% Performance Quart-12.26% Performance Half21.43%
Performance Year-51.6% Performance Year-to-date75.76% Volatility daily6.76% Volatility weekly15.12%
Volatility monthly30.99% Volatility yearly107.36% Relative Volume112.06% Average Volume165.09 K
New High New Low

News

2019-03-06 06:00:00 | Bioblast Announces Effectiveness of Eight to One Reverse Split

2019-02-19 09:35:00 | 4 Healthcare Stocks Looking to Start Strong on Tuesday 2/19/19

2019-02-19 08:00:00 | Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma

2019-02-19 07:45:29 | Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics

2019-02-14 19:05:42 | Bioblast Pharma Announces Collaboration with Team Sanfilippo to Evaluate Trehalose for the Treatment of Sanfilippo Syndrome

2019-01-11 16:05:00 | Bioblast Pharma Ltd. Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Non-Compliance

2018-11-20 08:45:00 | New Healthcare Trends Have Investors Looking at 4 Stocks

2018-11-19 16:15:00 | Bioblast Pharma Ltd. Announces Entry Into Merger Agreement to Acquire Enlivex Therapeutics Ltd. to Advance Clinical Stage Immunotherapeutic Drug Pipeline for the Treatment of Life-Threatening Diseases Sepsis, GvHD and Solid Tumors

2018-07-26 16:15:00 | Bioblast Pharma Ltd. Corporate and Management Update

2018-05-24 15:47:21 | Who Are The Top Investors In Bioblast Pharma Ltd NASDAQ:ORPN?

2018-05-08 08:45:16 | Benzinga Pro's 6 Stocks To Watch Today

2018-04-10 11:19:17 | What Kind Of Risk Should You Expect For Bioblast Pharma Ltd NASDAQ:ORPN?

2018-02-22 11:13:20 | Should You Be Concerned About Bioblast Pharma Ltd’s NASDAQ:ORPN Investors?

2018-01-17 17:12:42 | ICYMI: Shutterfly Downgrade, BioBlast Price Action, Blockchain ETFs

2017-11-03 14:39:31 | Should You Invest In The Healthcare Stock Bioblast Pharma Ltd ORPN?

2017-11-02 07:53:43 | Bio Blast reports 3Q loss

2017-11-02 07:30:00 | Bioblast Pharma Reports Third Quarter 2017 Financial Results

2017-10-06 08:00:00 | Today's Research Reports on Trending Tickers: Alibaba and JD.com

2017-09-25 07:00:00 | Bioblast Announces Effectiveness of Five to One Reverse Split

2017-09-18 07:00:00 | Kamada Announces CFO Transition

2017-08-04 21:31:57 | Bio Blast reports 2Q loss

2017-08-04 16:15:00 | Bioblast Pharma Reports Second Quarter 2017 Financial Results

2017-06-05 16:15:00 | Bioblast Pharma to Seek Strategic Alternatives Including Partnership and Merger Opportunities

2017-05-26 16:20:38 | Bio Blast reports 1Q loss

2017-05-26 16:15:00 | Bioblast Pharma Reports First Quarter 2017 Financial Results

2017-04-17 16:48:30 | Bioblast Pharma Announces Plans in Response to Nasdaq Notifications Regarding Stockholders’ Equity and Minimum Bid Requirements

2017-04-06 16:56:17 | Bioblast Announces Termination of Securities Offering

2017-04-06 16:01:00 | Bioblast Pharma Announces Termination of Securities Offering

2017-03-10 16:05:00 | Bioblast Pharma Announces Receipt of Nasdaq Notification Regarding Stockholders’ Equity

2017-02-24 08:12:42 | Bio Blast reports 4Q loss

2017-02-24 08:00:00 | Bioblast Pharma Reports Fourth Quarter and Year End 2016 Financial Results

2017-02-01 16:01:00 | Bioblast Pharma Provides Clinical and Development Updates on Trehalose as a Potential Therapeutic for OPMD and Other Neurodegenerative Diseases

2017-01-26 08:00:00 | Bioblast Pharma to Host Key Opinion Leader Lunch Focused on Orphan Neurological Diseases on February 2

2017-01-19 08:43:01 | Bioblast ORPN SCA3 Drug Favorable in Phase IIa Study

2017-01-18 08:01:00 | 8:01 am Bio Blast Pharma announces results of a 6-month open label Phase 2a study that also included an additional six-month follow-up period investigating trehalose in patients with Spinocerebellar Ataxia Type 3

2017-01-18 08:00:00 | Bioblast Announces Phase 2a Results of Trehalose in Patients with Spinocerebellar Ataxia Type 3 SCA3

2016-11-29 08:09:30 | Bio Blast reports 3Q loss

2016-11-29 08:00:00 | Bioblast Pharma Reports Third Quarter 2016 Financial Results

2016-10-27 13:04:04 | BIOBLAST PHARMA LTD. Financials

2016-10-24 06:00:00 | Bioblast Announces Results of Trehalose Clinical Study

2016-10-17 09:14:01 | Allergan AGN Gains Rights to RTGel from UroGen Pharma

2016-09-26 08:00:00 | Bioblast’s Special Medical Advisor to Make a Presentation Today On Trehalose as a Potential Therapeutic Agent for OPMD

2016-09-16 07:37:00 | 5 Stocks to Trade for Big Breakout Gains

2016-09-12 06:00:00 | Bioblast Pharma Reports Results of a Clinical Trial of Trehalose in Oculopharyngeal Muscular Dystrophy OPMD Patients

2016-09-07 08:00:00 | Bioblast Pharma Announces Presentation at the 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016

2016-08-25 08:11:36 | Bio Blast reports 2Q loss

2016-08-25 08:00:00 | Bioblast Pharma Reports Second Quarter 2016 Financial Results

2016-08-11 11:26:03 | 3 Healthcare Stocks Poised to Beat Q2 Earnings

2016-07-01 08:29:12 | Tesaro TSRO in Focus: Stock Adds 8.6% in Session

2016-06-29 08:30:12 | Calithera Biosciences CALA Jumps: Stock Rises 7.6%